BioSpace News Archive

Inhibrx, Inc., a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced it will be presenting at multiple upcoming scientific conferences.

Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) today announced that new and updated preclinical data for MRT-2359, the company’s lead drug candidate and a potent and selective GSPT1-directed MGD targeting MYC-driven solid tumors, will be presented at the 5th Annual Targeted Protein Degradation Summit, taking place Oct. 25-28 in Boston.

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2022 financial results on Thursday, October 27, 2022, after the close of the U.S. financial markets.

NANO-X IMAGING LTD, an innovative medical imaging technology company, will be hosting its first in-person ARC Day, with a demonstration of its Nanox.ARC imaging system at the Company’s headquarters in Neve Ilan, Israel, on Nov. 15-17.

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) and its product candidate, ridinilazole, today had an oral podium presentation at IDWeek 2022.

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced poster presentations to be made at upcoming medical meetings.

Biohaven Ltd. announced the pricing of the public offering of 25,000,000 of its common shares, at a public offering price of $10.50 per common share.